Hospital touts first EU-authorized drug to treat AADC deficiency

A drug developed by National Taiwan University Hospital (NTUH) has been approved for sale in the European Union for the treatment of aromatic-L-amino acid decarboxylase (AADC) deficiency, a rare life-threatening disorder that affects children, the hospital said Friday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)